ClinicalTrials.gg
CompletedNCT07034768Updated Mar 12, 2026

A Study to Evaluate EDG-7500 in People With Renal Impairment

A Phase 1 interventional study of EDG-7500 in Renal Impairments, sponsored by Edgewise Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Edgewise Therapeutics, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.

02

Conditions studied

  • Renal Impairments
03

In context

Lead sponsor

Edgewise Therapeutics, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

All Participants

  • Adult, male or female, 18-75 years of age, inclusive
  • Female and male participants must follow protocol-specified guidance
  • Continuous non-smoker or light smoker (≤ 5 cigarettes per day or equivalent) for at least 3 months prior to dosing
  • ≥ 18.0 and ≤ 40.0 kg/m2 at the screening visit.

Participants with Severe, Moderate and Mild Renal Impairment (RI)

  • With the exception of RI and other stable diseases, participant is sufficiently healthy for study participation including the following:

    • Heart rate ≥ 40 bpm and ≤ 110 bpm.
    • interval ≤ 500 msec and has findings considered normal or not .
    • Liver function test including ≤ , AST ≤ ULN, and total ≤ 1.5 ULN
  • Has impaired renal function as determined by :

    • eGFR \<30 mL/min, not requiring hemodialysis, for participants with severe RI.
    • eGFR ≥30 but \<60 mL/min for participants with moderate RI.
    • eGFR ≥60 but \<90 mL/min for participants with mild RI.
  • Has stable renal function with no clinically significant change in renal status at least 28 days prior to dosing and is not currently or has not been previously on dialysis for at least 1 year.

Participants with Normal Renal Function

  • Medically healthy, including the following:

    • Blood pressure ≥ 90/40 mmHg and ≤ 150/95 mmHg
    • Heart rate ≥ 40 bpm and ≤ 100 bpm
    • QTcF interval ≤ 470 msec and has ECG findings considered normal or not clinically significant
    • Liver function test including ALT ≤ ULN, AST ≤ ULN, and total bilirubin ≤1.5x ULN
    • Normal renal function with eGFR ≥ 90 mL/min

Exclusion Criteria:

All Participants

  • History or presence of alcohol or drug abuse within the past 2 years prior to dosing.
  • Female participant with a positive pregnancy test at the screening visit or at check-in or who is lactating.
  • Positive urine or breath alcohol results. Unable to refrain from or anticipates the use of any drugs.
  • Positive results for , , or .
  • Donation of blood or significant blood loss within 56 days prior to the first dosing.
  • Plasma donation within 7 days prior to the first dosing.
  • Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to dosing.

Participants with Severe, Moderate, and Mild RI (Cohorts 1, 2, and 4)

  • History or presence of renal artery stenosis.
  • Renal transplant or nephrectomy in ≤ 5 years.
  • Diabetes confirmed with > 8.5%.

Participants with Normal Renal Function (Cohort 3)

-History of any illness that might confound the results of the study or poses an additional risk to the participant by their participation in the study.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Healthy Volunteers

    Drug: EDG-7500

  • Experimental
    Severe Renal Impairment

    Drug: EDG-7500

  • Experimental
    Moderate Renal Impairment

    Drug: EDG-7500

  • Experimental
    Mild Renal Impairment

    This arm will only be conducted if deemed necessary based on data in participants with moderate and severe renal impairment

    Drug: EDG-7500

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve from time zero to last quantifiable concentration (AUC0-last)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUC0-last)

    Time frame: Pre-dose to day 11

  2. Area under the curve from time zero to extrapolated infinite time (AUC0-inf)

    Area under the plasma concentration time-curve from zero to extrapolated infinite time (AUC0-inf)

    Time frame: Pre-dose to day 11

  3. Maximum observed plasma concentration (Cmax)

    Time frame: Pre-dose to day 11

  4. Observed plasma concentration at the end of the dosing interval (C24)

    Time frame: Pre-dose to day 11

  5. Time to reach maximum observed plasma concentration (Tmax)

    Time frame: Pre-dose to day 11

  6. Plasma elimination half-life (T1/2)

    The time measured for the plasma concentration to decrease by one half.

    Time frame: Pre-dose to day 11

Secondary outcomes

  1. Amount of unchanged drug excreted in urine from zero to 24 hours post dose (Ae0-24)

    Time frame: From day -1 to day 11

  2. Fraction of drug excreted unchanged in urine (fe)

    Time frame: From day -1 to day 11

  3. Renal clearance

    Time frame: From day -1 to day 11

07

Study locations

2 sites
  • The University of Miami Division of Clinical Pharmacology
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 24, 2025
StartActual
Jul 22, 2025
Primary completionActual
Dec 22, 2025
CompletionActual
Dec 26, 2025
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07034768
Lead sponsor
Edgewise Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Jul 22, 2025
Primary completion
Dec 22, 2025
Completion
Dec 26, 2025
Last update
Mar 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDG-7500

Start the discussion